Group One Trading’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $58K | Sell |
12,500
-7,900
| -39% | -$20.5K | ﹤0.01% | 5295 |
|
|
2026
Q1 | $56.9K | Buy |
20,400
+8,400
| +70% | +$25.6K | ﹤0.01% | 5166 |
|
|
2025
Q4 | $49.9K | Sell |
12,000
-27,200
| -69% | -$143K | ﹤0.01% | 5606 |
|
|
2025
Q3 | $166K | Sell |
39,200
-43,400
| -53% | -$163K | ﹤0.01% | 4879 |
|
|
2025
Q2 | $174K | Buy |
82,600
+42,000
| +103% | +$62.8K | ﹤0.01% | 4477 |
|
|
2025
Q1 | $49.5K | Sell |
40,600
-5,100
| -11% | -$7.15K | ﹤0.01% | 5169 |
|
|
2024
Q4 | $59K | Buy |
45,700
+43,600
| +2,076% | +$104K | ﹤0.01% | 4935 |
|
|
2024
Q3 | $5.78K | Buy |
+2,100
| New | +$5.16K | ﹤0.01% | 5821 |
|
|
2024
Q1 | – | Sell |
-400
| Closed | -$664 | – | 7350 |
|
|
2023
Q4 | $664 | Hold |
400
| – | – | ﹤0.01% | 7048 |
|
|
2023
Q3 | $768 | Hold |
400
| – | – | ﹤0.01% | 7265 |
|
|
2023
Q2 | $576 | Hold |
400
| – | – | ﹤0.01% | 7351 |
|
|
2023
Q1 | $840 | Sell |
400
-2,600
| -87% | -$4.2K | ﹤0.01% | 6821 |
|
|
2022
Q4 | $3.39K | Sell |
3,000
-7,100
| -70% | -$9.46K | ﹤0.01% | 6493 |
|
|
2022
Q3 | $16K | Sell |
10,100
-2,100
| -17% | -$3.92K | ﹤0.01% | 6217 |
|
|
2022
Q2 | $16K | Sell |
12,200
-15,100
| -55% | -$21.7K | ﹤0.01% | 6444 |
|
|
2022
Q1 | $44K | Buy |
27,300
+9,400
| +53% | +$18.2K | ﹤0.01% | 6181 |
|
|
2021
Q4 | $37K | Sell |
17,900
-17,100
| -49% | -$48.8K | ﹤0.01% | 6547 |
|
|
2021
Q3 | $136K | Buy |
35,000
+17,900
| +105% | +$60.7K | ﹤0.01% | 5585 |
|
|
2021
Q2 | $55K | Buy |
17,100
+14,500
| +558% | +$51.6K | ﹤0.01% | 6484 |
|
|
2021
Q1 | $6K | Sell |
2,600
-3,200
| -55% | -$7.17K | ﹤0.01% | 7200 |
|
|
2020
Q4 | $13K | Sell |
5,800
-2,500
| -30% | -$6.56K | ﹤0.01% | 5696 |
|
|
2020
Q3 | $22K | Sell |
8,300
-8,600
| -51% | -$24.1K | ﹤0.01% | 5079 |
|
|
2020
Q2 | $52K | Buy |
16,900
+1,000
| +6% | +$2.52K | ﹤0.01% | 4327 |
|
|
2020
Q1 | $31K | Sell |
15,900
-15,900
| -50% | -$38.7K | ﹤0.01% | 4002 |
|
|
2019
Q4 | $91K | Sell |
31,800
-2,800
| -8% | -$9.73K | ﹤0.01% | 3693 |
|
|
2019
Q3 | $127K | Buy |
34,600
+400
| +1% | +$1.45K | ﹤0.01% | 3401 |
|
|
2019
Q2 | $142K | Sell |
34,200
-52,900
| -61% | -$229K | ﹤0.01% | 3093 |
|
|
2019
Q1 | $445K | Buy |
87,100
+29,300
| +51% | +$141K | 0.01% | 2039 |
|
|
2018
Q4 | $198K | Sell |
57,800
-108,100
| -65% | -$516K | ﹤0.01% | 2693 |
|
|
2018
Q3 | $997K | Buy |
165,900
+12,700
| +8% | +$69.9K | 0.01% | 1700 |
|
|
2018
Q2 | $974K | Buy |
153,200
+95,900
| +167% | +$467K | 0.01% | 1749 |
|
|
2018
Q1 | $272K | Sell |
57,300
-127,600
| -69% | -$595K | ﹤0.01% | 2552 |
|
|
2017
Q4 | $618K | Buy |
184,900
+47,200
| +34% | +$119K | ﹤0.01% | 2089 |
|
|
2017
Q3 | $292K | Buy |
137,700
+32,800
| +31% | +$65K | ﹤0.01% | 2493 |
|
|
2017
Q2 | $258K | Buy |
104,900
+91,600
| +689% | +$244K | ﹤0.01% | 2455 |
|
|
2017
Q1 | $31K | Buy |
+13,300
| New | +$20K | ﹤0.01% | 3667 |
|
Other funds holding GALT
WANY
Group One Trading's GALT Position: Q2 2026 in Review
Group One Trading opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 13,753 shares worth $63.8K. The stake represents ﹤0.01% of the portfolio and ranks #5202 among its holdings. This is a return to the name: Group One Trading previously reported a position in GALT as recently as Q3 2025.
Group One Trading first reported a position in GALT in Q3 2017 and has held it in 15 quarters since. The position peaked at $690K in Q2 2018. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Group One Trading held 13,753 shares of Galectin Therapeutics worth $63.8K as of Q2 2026.
- Galectin Therapeutics was a new Group One Trading position in Q2 2026.
- Galectin Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #5202 holding.
- Group One Trading first reported a position in Galectin Therapeutics in Q3 2017 and has held it in 15 quarters since.
- Group One Trading's Galectin Therapeutics position peaked at $690K in Q2 2018.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.